Federal Circuit Reverses JMOL and Reinstates Jury Verdict in Teva V. Lilly

Why It Matters

The ruling reinforces enforceability of method‑of‑use patents in the biotech sector, protecting substantial revenue streams for innovators. It also signals to competitors that broad therapeutic claims can survive validity challenges, shaping future litigation and licensing strategies.

Key Takeaways

• Federal Circuit reinstated $176.5 million jury verdict for Teva
• Court found patents satisfied written description requirement for migraine-use methods
• Enablement upheld because antibody genus was already well‑known in field
• Decision strengthens patent protection for biologic drug indications
• Lilly faces potential additional liability beyond the reinstated award

Pulse Analysis

The Federal Circuit’s decision in Teva v. Lilly marks a pivotal moment for patent law in the biologics arena. By upholding Teva’s method‑of‑use claims for migraine‑treating antibodies, the court affirmed that detailed functional descriptions can meet the written description standard even when the underlying molecules are well known. This clarification benefits companies that rely on broad therapeutic claims to protect their R&D investments, especially as the market for monoclonal antibodies expands across neurology and immunology.

In its analysis, the appellate panel emphasized that the patents were directed to the use of antibodies, not the antibodies themselves, and that the prior art already disclosed the relevant antibody genus. Consequently, the court found no deficiency in enablement, rejecting Lilly’s argument that the patents amounted to a mere screening exercise. This reasoning sets a robust precedent for future disputes involving method claims, suggesting that courts will look beyond literal claim language to the practical knowledge of a skilled artisan when assessing validity.

For the business community, the reinstated $176.5 million verdict restores a significant revenue boost for Teva and underscores the financial stakes of patent enforcement in high‑margin therapeutic areas. Lilly now faces not only the restored damages but also the prospect of additional liability if further infringement is proven. The ruling may prompt competitors to re‑evaluate their patent portfolios and licensing approaches, potentially accelerating settlement negotiations and influencing strategic decisions around antibody development pipelines.